New pathology item to detect RET gene activating variant status

This page provides details regarding the 1 August 2026 changes to pathology services on the Medicare Benefits Schedule (MBS).

Page last updated: 04 August 2026

From 1 August 2026, changes will apply to selected Medicare Benefits Schedule (MBS) pathology services. The changes include one new genetic testing item.

Further information can be found in the factsheet below:

Word Version -  tumour tissue testing to detect RET gene activating variant status.DOCXWord Version - tumour tissue testing to detect RET gene activating variant status.DOCX
PDF Version -  tumour tissue testing to detect RET gene activating variant status.pdfPDF Version - tumour tissue testing to detect RET gene activating variant status.pdf

In this section